Modulation of the Immune Response in Vitro and in Vivo by Splenocytes from Tumor-Bearing Mice

  • Steven C. Specter
  • Isao Kamo
  • Herman Friedman
Chapter

Abstract

Individuals with neoplasia often show markedly suppressed immune responses (1–3). However, the nature and mechanism of immune dysfunction in individuals with malignancy is still far from clear. In this regard, it is now generally accepted that oncogenic viruses, as well as some carcinogenic agents are immunosuppressive (4,5). Furthermore, immunologic impairment is often observed in experimental animals transplanted with tumor cells which appear free of oncogenic viruses. In addition, soluble factors capable of inhibiting immune responses have been found in serum and ascitic fluids in tumor bearing individuals (6–8). Much attention has been focused in recent years on purification and characterization of such immunosuppressive factors, including those associated with neoplasia as well as other “natural” immunosuppressive substances, presumably alpha globulins, in serum from patients with a variety of diseases. However, the target ce11(s) involved in tumor associated immunosuppression induced by such substances is unknown.

Keywords

Spleen Cell Ascitic Fluid Sheep Erythrocyte Plaque Form Cell Lymphocytic Choriomeningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burnet, H.M., Brit. Med. Bull. 20:159, 1967.Google Scholar
  2. 2.
    Miller, D.E., Cancer Res. 28:1441, 1968.PubMedGoogle Scholar
  3. 3.
    Alsenberg, A.C. in Proc. Internat’1. Conf. Leukemia Lymphoma, Zarofonetis, C.J.D. (ed) p. 873 Lea and Febiger, Phila., 1968.Google Scholar
  4. 4.
    Dent, P., Prog. Med. Virol. 14:1, 1972.PubMedGoogle Scholar
  5. 5.
    Ceglowski, W.S. and Friedman, H., (eds) Virus Tumorigenesis and Immunogenesis. Academic Press, New York, 1973.Google Scholar
  6. 6.
    Mocarelli, P., Villa, L.V., Garotta, G., Porta, C., Bigi, G. and Clerici, E., J. Immunol. 111:873, 1973Google Scholar
  7. 7.
    Chan, P.L. and Sinclair, N.R.S.C., J. Nat. Cancer Inst. 48: 1629, 1972.Google Scholar
  8. 8.
    Hrsak, I. and Marotti, T., Eur. J. Cancer9:717, 1973.Google Scholar
  9. 9.
    Loring, M. and Schlesinger, M., Cancer Res., 30:2204, 1970.PubMedGoogle Scholar
  10. 10.
    Laux, D. and Laush, R.N., J. Immunol. 112:1900, 1974.PubMedGoogle Scholar
  11. 11.
    Jerne, N.K., Nordin, A.A. and Henry, C., in Cell Bound Antibodies Amos B. and Koprowski, H. (eds) p. 109: Wistar Inst. Press, Phila, 1963.Google Scholar
  12. 12.
    Marbrook, J., Lancet 2: 1279, 1967.PubMedCrossRefGoogle Scholar
  13. 13.
    Kateley, J.R., Kamo, I., Kaplan, G. and Friedman, H., J. Nat’l Cancer Inst. 53:1371s 1974.Google Scholar
  14. 14.
    Potter, M., in The Molecular Biology of Cancer, Busch, H. (ed) p. 536, Academic Press, New York, 1974.Google Scholar
  15. 15.
    Giacomoni, D., Katzmann, J., Chandra, S. and Heller, P. in “Tumor Virus Infection and Immunity”, ASM Symposium, Friedman, H., Crowell, R. and Prier, J. (eds), University Park Press, in press, 1975.Google Scholar
  16. 16.
    Tanapatchaiyapong, P. and Zolla, S., Science 186:748, 1974.PubMedCrossRefGoogle Scholar
  17. 17.
    Kamo, I., Patel, C., Kateley, J. and Friedman, H., J. Immunol. 114:1749, 1975.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Steven C. Specter
    • 1
  • Isao Kamo
    • 1
  • Herman Friedman
    • 1
  1. 1.Department of Microbiology and ImmunologyAlbert Einstein Medical CenterPhiladelphiaUSA

Personalised recommendations